Skip to content
Clinical Trials – home
Not yet recruiting

Neoadjuvant Pembrolizumab and Porustobart for Resectable pMMR/MSS Colon Cancer: A Phase 2 Study of Efficacy and Safety in Eligible Patients

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The trial focuses on patients with pMMR/MSS colon cancer, a type of colon cancer that can be removed by surgery and has specific genetic characteristics. The treatment being tested combines an infusion of pembrolizumab, a medication that helps the immune system recognize and attack cancer cells, with an infusion of Porustobart, a new drug being studied for its ability to stop tumor growth.

The purpose of the study is to see how many patients have a major reduction in tumor size before surgery when given these medicines. Participants receive several doses of the two infusions over a short period before their planned operation, after which the surgery is performed to remove the tumor. Researchers will then monitor the patients for recovery and any side effects.

After surgery, patients are followed for several months to check for any return of cancer and to assess overall health. The study tracks how well the treatment was tolerated and whether it helped achieve a complete disappearance of detectable tumor tissue. Important terms include neoadjuvant, which means treatment given before surgery, and major pathologic response, which describes a situation where only a very small amount of tumor remains.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Randomization and Treatment Assignment

    After joining the study, you will be randomly placed into one of the treatment groups. This determines which medication schedule you will receive.

  2. Step 2

    First Intravenous Infusion

    You will receive an IV infusion of the assigned drug(s) at the clinic.

    If assigned to pembrolizumab, the dose is 200 mg given as a solution for infusion.

    If assigned to porustobart, the dose is 0.3 mg per kilogram of body weight, also given as an IV infusion.

  3. Step 3

    Repeated Infusions According to Schedule

    You will return to the clinic for additional infusions on the schedule defined by the study protocol.

    Each infusion uses the same dose as the first infusion.

    The total number of infusions and the interval between them are specified in the trial plan.

  4. Step 4

    Pre‑Surgical Evaluation

    After completing the neoadjuvant (pre‑surgery) infusions, you will undergo assessments to confirm that you are ready for surgery.

    These assessments may include imaging tests and laboratory checks.

  5. Step 5

    Surgical Removal of Tumor

    You will undergo surgery to remove the colon tumor and nearby lymph nodes.

    The surgery is performed according to standard clinical practice.

  6. Step 6

    Post‑Surgical Follow‑Up Visits

    Following surgery, you will attend scheduled visits to monitor recovery and to evaluate the pathologic response of the tumor.

    During these visits, doctors will review pathology results and may perform additional examinations.

  7. Step 7

    Long‑Term Safety and Survival Monitoring

    You will continue to be monitored for safety, disease recurrence, and overall health for a period defined by the study.

    These visits may include physical examinations, imaging studies, and laboratory tests.

Who can join the trial?

13 criteria

  • Must be able to read, understand, and sign a written informed consent form before any study‑related procedures that are not part of normal care.
  • Must be at least 18 years old at the time of signing the consent.
  • Must have colon cancer that is an adenocarcinoma (cancer that starts in gland cells) that doctors think can be removed by surgery, and the tumor must show:
    • “pMMR” – meaning all four mismatch‑repair proteins (MLH1, MSH2, MSH6, PMS2) are present, tested by a lab method called immunohistochemistry, or
    • “MSS” – meaning the DNA microsatellites are stable, tested by PCR or NGS (genetic tests).
    • Must have an ECOG Performance Status of 0 or 1, which means they are fully active or have only minor symptoms that do not limit normal activities.
    • Must provide a sufficient tumor tissue sample:
      • A preserved tissue block (FFPE) or at least 10 unstained slides, taken within the last 3 months.
      • The sample must be from a core needle, excisional, or endoscopic biopsy (not a fine‑needle lung biopsy).
      • A pathology report must accompany the sample.
      • Must have adequate organ and bone‑marrow function as shown by lab tests:
        • Blood (hematological) function: absolute neutrophil count ≥ 1.5 × 10⁹/L, platelets ≥ 100 × 10⁹/L, hemoglobin ≥ 8 g/dL (a transfusion is allowed if needed).
        • Liver function: bilirubin ≤ 1.5 × the normal limit (or ≤ 3.0 × if they have Gilbert syndrome), AST and ALT each ≤ 2.5 × normal.
        • Kidney function: creatinine clearance ≥ 40 mL/min, calculated with the Cockcroft‑Gault equation.
        • Must follow birth‑control rules:
          • Women of childbearing potential must not be breastfeeding, must have a negative pregnancy test within 72 hours before treatment, must use contraception during treatment and for 5 months after the last dose, and must not donate eggs.
          • Men who have sex with women who could become pregnant must use contraception during treatment and for 7 months after the last dose, and must not donate sperm. Men who have no sperm (azoospermic) are exempt.

Who cannot join the trial?

16 criteria

  • If you are currently in another clinical trial or have been in one with a new (investigational) drug within the past 3 weeks, you cannot join.
  • If you need surgery very soon because of a serious problem (for example, a risk that the colon could tear), you cannot join.
  • If you have already received chemotherapy, radiation, or other cancer medicines for colon cancer, or have taken special immune‑system drugs called immune checkpoint inhibitors (targets include CTLA-4, PD‑1, PD‑L1), you cannot join.
  • If you are taking strong anti‑inflammatory or immune‑suppressing medicines (such as high‑dose steroids) within 1 week before the first dose of the study drug, you cannot join. Low‑dose daily steroids, inhaled or skin‑applied steroids, and steroids used only for contrast‑agent allergies are allowed.
  • If you have ever had a severe allergic reaction (grade 3 or higher) to a fully human monoclonal antibody, or you have lung conditions such as interstitial lung disease or previous pneumonitis that needed steroids, you cannot join.
  • If you have an active or recent (within 2 years) autoimmune disease that required strong medicines (like disease‑modifying drugs, steroids, or other immune‑suppressing drugs), you cannot join. Autoimmune problems that only need hormone replacement or skin treatments are allowed.
  • If you have serious heart or blood‑vessel problems, such as a recent stroke, a heart attack within the last 6 months, unstable chest pain (angina), moderate or worse heart failure (NYHA class II or higher), or a dangerous irregular heartbeat that needs medication and could stop surgery, you cannot join.
  • If you had a major operation (big surgery) within the last 4 weeks, you cannot join.
  • If you currently have an infection that needs treatment (for example, a bacterial or viral infection), you cannot join.
  • If you have an active hepatitis B infection (positive hepatitis B surface antigen) or an active hepatitis C infection (positive hepatitis C RNA), you cannot join. Past hepatitis B infection that is resolved may be allowed, but current active infection is not.
  • If you test positive for HIV‑1 or HIV‑2 and your infection is not well‑controlled (you need a CD4 count above 350 cells/µL, an undetectable viral load, and stable antiretroviral therapy), you cannot join.
  • If you received a live vaccine (such as certain flu, yellow fever, or measles vaccines) within the past 28 days, you cannot join.
  • If you had another cancer that was still active in the past 3 years, you cannot join, except for skin cancers like basal or squamous cell carcinoma, superficial bladder cancer, or very early‑stage prostate, cervical, or breast cancers that were cured and have a very low chance of returning.
  • If you have other serious or uncontrolled medical problems that are not listed above, you cannot join.
  • If you have a psychiatric condition (mental health disorder) or a substance‑abuse problem that would make it difficult to follow the study requirements, you cannot join.
  • If you are legally unable to give consent or have limited legal capacity, you cannot join.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • pembrolizumab

    is an intravenous medicine that helps the immune system recognize and attack cancer cells. In this study it is given before surgery (neoadjuvant) to see if it can shrink or eliminate the tumor in patients with colon cancer that has a normal mismatch‑repair system. Researchers are testing different timing schedules of the infusion to find the best way to use the drug.

  • Porustobart

    is a new experimental drug that is also given by IV infusion before surgery. It is being studied together with pembrolizumab to see if the combination works better than pembrolizumab alone. The trial is looking at how well Porustobart helps the tumor respond to treatment and whether it is safe for patients.

What is already known about the treatment

  • KEYTRUDA

    It is given by intravenous infusion, meaning the medication is mixed in a liquid and slowly injected into a vein. Pembrolizumab is an approved cancer drug that is widely used and studied in many medical papers. It is mainly used to treat several cancers, including certain types of colon cancer that cannot be removed by surgery. It works by blocking a protein called PD‑1, which lets the body’s immune cells see and attack tumor cells, and it belongs to the class of immune‑checkpoint inhibitors.

  • Porustobart

    It is also given by intravenous infusion, a liquid that is injected directly into a vein. Porustobart is an experimental medicine that is still being tested in clinical trials and has not yet received regular approval. It is being examined for use together with pembrolizumab in patients with resectable colon cancer that has normal mismatch‑repair genes. It is thought to act on a specific cell pathway that slows tumor growth, placing it in the group of targeted cancer therapies.

Investigated diseases

Resectable proficient mismatch repair (pMMR) / microsatellite stable (MSS) colon cancer - The disease is a type of colon cancer in which the tumor cells retain normal DNA repair function (proficient mismatch repair) and do not show microsatellite instability, indicating a microsatellite stable status. It is considered resectable, meaning the primary tumor and any nearby lymph nodes can be surgically removed. The cancer typically begins as a growth in the lining of the colon and may enlarge locally, invading deeper layers of the bowel wall. Over time, if not controlled, it can spread to regional lymph nodes and eventually to distant organs.
Trial detailsLast updated 18 Nov 2026
Age18+ yearsPhasePhase IITrial ID2026-527233-58-00Protocol codeSOL1-201Estimated enrolment75 patientsSponsorSolstice Oncology Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.